Welcome to our dedicated page for Ventas SEC filings (Ticker: VTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Ventas鈥� filings can feel like sorting through hundreds of pages on rent escalators, triple-net lease covenants, and senior-housing occupancy rates. If you鈥檝e ever asked, 鈥淲here鈥檚 the dividend guidance hidden in Ventas鈥� annual report 10-K?鈥� or hunted for Ventas insider trading Form 4 transactions, you know the challenge.
Stock Titan solves it. Our platform ingests every Ventas quarterly earnings report 10-Q filing, 8-K, and proxy in real time, then delivers plain-English, AI-powered summaries. Need Ventas Form 4 insider transactions real-time? Get instant alerts. Trying to compare deferred rent trends quarter over quarter? Our AI highlights the numbers and adds context so you鈥檙e understanding Ventas SEC documents with AI instead of decoding footnotes.
You鈥檒l find more than a list of forms. We connect each document to what matters for a healthcare REIT: the 10-K section that forecasts SHOP margins, the 8-K paragraph announcing operator restructurings (Ventas 8-K material events explained), or the Ventas proxy statement executive compensation table that details incentive targets. Whether you鈥檙e scanning a Ventas annual report 10-K simplified for dividend coverage or running a quick Ventas earnings report filing analysis, the insights are ready in minutes鈥攏o spreadsheet gymnastics required. Monitor Ventas executive stock transactions Form 4, track payout ratios, and see AI-generated red-flag alerts across ALL filing types the moment they hit EDGAR.
Block, Inc. (ticker: XYZ) filed a Form 144 to notify the SEC of an intended sale of 2,800 shares of its common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE around 15 July 2025. At the stated aggregate market value of $190,568, the proposed sale equals roughly 0.0005 % of the company鈥檚 615.0 million shares outstanding, indicating a very limited dilution effect.
The securities being sold were originally received as restricted-stock grants on three separate dates鈥�02/20/2024 (1,442 shares), 11/20/2023 (961 shares) and 01/03/2023 (397 shares). No cash was paid at acquisition, implying the grants were part of equity-based compensation.
Over the last three months, the same reporting person executed nine open-market sales totaling 22,918 shares for gross proceeds of approximately $1.45 million. Even when combined with the new notice, total insider sales remain immaterial relative to Block鈥檚 share count and typical daily trading volume.
Form 144 requires the insider to certify that they possess no undisclosed material adverse information and, if relying on a Rule 10b5-1 plan, to disclose the plan-adoption date. No such plan date is provided in the filing.
FAQ
What is the current stock price of Ventas (VTR)?
What is the market cap of Ventas (VTR)?
What is the primary focus of Ventas, Inc.?
How does Ventas generate its revenue?
What types of properties are included in Ventas' portfolio?
In which regions does Ventas operate?
How is Ventas positioned within the healthcare real estate market?
What factors contribute to the company鈥檚 financial stability?
How does Ventas ensure operational excellence?
